SLC2A1 and epilepsy: Moreover, KDTs are the mainstay of treatment for glucose transporter type 1 deficiency syndrome (GLUT1-DS, OMIM 606777), a rare metabolic encephalopathy [4] characterized by developmental impairment, epilepsy, and a movement disorder.